Millie
your market intelligence analyst
Search Results
Edit Save
175 results
Hoffmann-La Roche (EU) 05/14/2020 01:00
Basel, 14 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase II CITYSCAPE trial, the first randomised study evaluating the efficacy and safety of tiragolumab plus Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC).
Hoffmann-La Roche (EU) 05/11/2020 08:15
Basel, 11 Mai 2020- On May 10th 2020 Dr. h.c. Fritz Gerber died in his 92nd year. For more than two decades, he had shaped Roche's development into a leading global healthcare company in an exceptionally successful dual role as Group CEO (1978-1998) and Chairman of the Board (1978-2001). He remained closely associated with Roche throughout his life as Honorary Chairman. Starting at the end of the 1970s, Fritz Gerber led the company from a difficult situation to new success. Under his leadership, Roche's Group structures were fundamentally renewed and decentralized– ranging from focusing on the core businesses to modernizing the capital structure. This created a fundamental change at Roche that still encourages entrepreneurial thinking today.
Hoffmann-La Roche (EU) 03/14/2020 05:00
Basel, 14 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that, even under the new federal guidelines on the COVID-19 situation (coronavirus), the Annual General Meeting will continue to take place on 17 March in accordance with an exemption provided for by the cantonal authorities Basel-Stadt.
Hoffmann-La Roche (EU) 03/12/2020 07:00
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Hoffmann-La Roche (EU) 02/07/2020 01:00
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Hoffmann-La Roche (EU) 01/31/2020 06:55
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).
Hoffmann-La Roche (EU) 01/23/2020 08:00
Roche will publish its Full Year Results for 2019 prior to the opening of the Swiss Stock Exchange on Thursday, 30 January 2020. 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00 PM PST (evening before) Release will be e-mailed and posted on the Roche IR website > here . Presentation slides will be posted on the Roche IR website > . We would like to invite all interested parties to participate or dial in to the event outlined below. Thursday, 30 January 2020, London The Full Year Presentation will be held at the London Stock Exchange, 10 Paternoster Square, London EC4M 7LS > Presenters:
Hoffmann-La Roche (EU) 12/13/2019 01:00
Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications